PŘEHLEDOVÉ ČLÁNKY Farmakologická léčba osteoporózy a prevence zlomenin: doporučení pro klinickou praxi | E23 / Vnitř Lék. 2024;70(2):E7-E23 / VNITŘNÍ LÉKAŘSTVÍ www.casopisvnitrnilekarstvi.cz 84. Kendler DL, Marin F, Zerbini CAF, et al. Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial. Lancet. 2018;391:230–240. 85. Saag KG, Petersen J, Brandi ML, et al. Romosozumab or alendronate for fracture prevention in women with osteoporosis. N Engl J Med. 2017;377:1417–1427. 86. Lindsay, R., Cosman, F., Zhou, H., et al. (2006). A novel tetracycline labeling schedule for longitudinal evaluation of the short-term effects of anabolic therapy with a single iliac crest bone biopsy: Early actions of teriparatide. Journal of Bone and Mineral Research, 21(3), 366–373. 87. Díez-Pérez A, Marin F, Eriksen EF, et al.. Effects of teriparatide on hip and upper limb fractures in patients with osteoporosis: a systematic review and meta-analysis. Bone. 2019;120(3):1–8. 88. Simpson EL, Martyn-St James M, Hamilton J (2020) Clinical effectiveness of denosumab, raloxifene, romosozumab, and teriparatide for the prevention of osteoporotic fragility fractures: a systematic review and network meta-analysis. Bone 130:115081 89. Orwoll ES, Scheele WH, Paul S, et al. (2003) The effect of teriparatide [human parathyroid hormone (1–34)] therapy on bone density in men with osteoporosis. J Bone Miner Res 18:9–17 90. Saag KG, Zanchetta JR, Devogelaer JP, et al. (2009) Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: thirty-six-month results of a randomized, doubleblind, controlled trial. Arthritis Rheum 60:3346–3355 91. Kaufman, J. M., Orwoll, E., Goemaere, S. et al. (2005). Teriparatide effects on vertebral fractures and bone mineral density in men with osteoporosis: Treatment and discontinuation of therapy. Osteoporosis International, 16(5), 510–516. 92. Lindsay, R., Scheele, W. H., Neer, R., et al. (2004). Sustained vertebral fracture risk reduction after withdrawal of teriparatide in postmenopausal women with osteoporosis. Archives of Internal Medicine, 164(18), 2024–2030. 93. Leder, B. Z., Tsai, J. N., Uihlein, A. V., et al. (2014). Two years of denosumab and teriparatide administration in postmenopausal women with osteoporosis (The DATA Extension Study): A randomized controlled trial. The Journal of Clinical Endocrinology and Metabolism, 99(5), 1694–1700. 94. Atkins, G. J., & Findlay, D. M. (2012). Osteocyte regulation of bone mineral: A little give and take. Osteoporosis International, 23(8), 2067–2079 95. Ominsky, M. S., Niu, Q. T., Li, C. et al. (2014). Tissue-level mechanisms responsible for the increase in bone formation and bone volume by sclerostin antibody. Journal of Bone and Mineral Research, 29(6), 1424–1430. 96. McCLung, M. R., Grauer, A., Boonen, S. et al. Bone, H. G. (2014). Romosozumab in postmenopausal women with low bone mineral density. N Engl J Med 2014, 370(5), 412–420. 97. Cosman F, Crittenden DB, Adachi JD et al (2016) Romosozumab treatment in postmenopausal women with osteoporosis. N Engl J Med 375(16):1532–1543 98. Saag KG, Petersen J, Brandi ML, et al. Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis. N Engl J Med 2017; 377:1417. 99. Lewiecki, E. M., Blicharski, T., Goemaere, S. et al. (2018). A phase III randomized placebo controlled trial to evaluate efficacy and safety of romosozumab in men with osteoporosis. The Journal of Clinical Endocrinology and Metabolism, 103(9), 3183–3193. 100. McClung MR, Brown JP, Diez-Perez A et al. (2018) Effects of 24 months of treatment with romosozumab followed by 12 months of denosumab or placebo in postmenopausal women with low bone mineral density: a randomized, double-blind, phase 2, parallel group study. J Bone Miner Res 33(8):1397–1406 101. Cosman F, Crittenden DB, Ferrari S et al (2018) Romosozumab FRAME Study: a post hoc analysis of the role of regional background fracture risk on nonvertebral fracture outcome. J Bone Miner Res 33(8):1407–1416 102. Langdahl BL, Libanati C, Crittenden DB, et al. Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial. Lancet 2017; 390:1585. 103. Leslie WD, Lix LM, Johansson H, et al. (2012) Does osteoporosis therapy invalidate FRAX for fracture prediction? J Bone Mineral Research 27:1243–1251 104. Fink HA, MacDonald R, Forte ML et al (2019) Long-term drug therapy and drug discontinuations and holidays for osteoporosis fracture prevention: a systematic review. Ann Intern Med 171:37–50 105. Dennison EM, Cooper C, Kanis JA, et al. (2019) Fracture risk following intermission of osteoporosis therapy. Osteoporos Int 30:1733–1743 106. Black DM, Schwartz AV, Ensrud KE et al (2006) Efects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA 296:2927–2938 107. Ravn P, Christensen JO, Baumann M, et al. (1998) Changes in biochemical markers and bone mass after withdrawal of ibandronate treatment: prediction of bone mass changes during treatment. Bone 22:559–564. 108. Watts NB, Chines A, Olszynski WP, et al. (2008) Fracture risk remains reduced one year after discontinuation of risedronate. Osteoporos Int 19:365–372 109. Black DM, Reid IR, Boonen S et al (2012) The efect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT). J Bone Miner Res 27:243–254 110. Cosman F, Cauley JA, Eastell R, et al. (2014) Reassessment of fracture risk in women after 3 years of treatment with zoledronic acid: when is it reasonable to discontinue treatment? J Clin Endocrinol Metab 99:4546–4554 111. Diez-Perez A, Adachi JD, Agnusdei D, et al. Treatment failure in osteoporosis IOF CSA Inadequate Responders Working Group. Osteoporos Int. 2012 Dec;23(12):2769-74. 112. Miller, P. D., Pannacciulli, N., Brown, J. Pet al. (2016). Denosumab or zoledronic acid in postmenopausal women with osteoporosis previously treated with oral bisphosphonates. The Journal of Clinical Endocrinology and Metabolism, 101(8), 3163–3170. 113. Cosman, F., Nieves, J. W., & Dempster, D. W. (2017). Treatment sequence matters: Anabolic and antiresorptive therapy for osteoporosis. Journal of Bone and Mineral Research, 32(2), 198–202. 114. Geusens, P., Marin, F., Kendler, D. L., et al. (2018). Effects of teriparatide compared with risedronate on the risk of fractures in subgroups of postmenopausal women with severe osteoporosis: The VERO trial. Journal of Bone and Mineral Research, 33(5), 783–794. 115. Leder, B. Z., Tsai, J. N., Uihlein, A. V., et al. (2015). Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): Extension of a randomised controlled trial. Lancet, 386(9999), 1147–1155. 116. Cosman F, Kendler DL, Langdahl BL, et al. Romosozumab and antiresorptive treatment: the importance of treatment sequence. Osteoporos Int. 2022 Jun;33(6):1243-1256. 117. Hui RL, Adams AL, Niu F et al (2017) Predicting adherence and persistence with oral bisphosphonate therapy in an integrated health care delivery system. J Manag Care Spec Pharm 23(4):503–512 118. Ross S, Samuels E, Gairy K, et al. A meta-analysis of osteoporotic fracture risk with medication nonadherence. Value Health. 2011;14:571–581.
RkJQdWJsaXNoZXIy NDA4Mjc=